Conolidine’s analgesic consequences stem from its conversation with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors within the central nervous process, conolidine modulates alternate molecular targets. A Science Advances review located that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://ignacyj184whl0.anchor-blog.com/profile